VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease

Blood

Volumn 121, Issue 12, 2013, Pages 2336-2339

  Eikenboom, Jeroen ^a   Federici, Augusto B ^b,i   Dirven, Richard J ^a   Castaman, Giancarlo ^c   Rodeghiero, Francesco ^c   Budde, Ulrich ^d   Schneppenheim, Reinhard ^e   Batlle, Javier ^f   Canciani, Maria Teresa ^b   Goudemand, Jenny ^g   Peake, Ian ^h   Goodeve, Anne ^h  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d Medilys Laborgesellschaft mbH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Hospital Teresa Herrera   (Spain)

^g UNIV LILLE   (France)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPEPTIDE; PROTEIN PRECURSOR;

ARTICLE; BLOOD GROUP O; CONTROLLED STUDY; FAMILY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NULL ALLELE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; GENETIC LINKAGE; GENETICS; HETEROZYGOTE DETECTION; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING;

CASE-CONTROL STUDIES; COHORT STUDIES; FACTOR VIII; FAMILY; GENETIC LINKAGE; HETEROZYGOTE DETECTION; HUMANS; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; VON WILLEBRAND DISEASE, TYPE 1; VON WILLEBRAND FACTOR;

MLCS; MLOWN;

EID: 84877929463     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-455089     Document Type: Article

References (23)

1. Sadler JE, Budde U, Eikenboom JC, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67: 395-424.
3. Wagner DD, Fay PJ, Sporn LA, et al. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987;84(7):1955-1959.
4. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996; 88(8):2951-2958.
5. Vischer UM, Ingerslev J, Wollheim CB, et al. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost. 1997;77(2):387-393.
6. van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 1999;94(1): 179-185.
7. Nossent AY, VAN Marion V, VAN Tilburg NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost. 2006;4(12):2556-2562.
8. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10): 4979-4985.
9. Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3(10):2228-2237.
10. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
11. Lian EC, Deykin D. Diagnosis of von Willebrand’s disease. A comparative study of diagnostic tests on nine families with von Willebrand’s disease and its differential diagnosis from hemophilia and thrombocytopathy. Am J Med. 1976;60(3):344-356.
12. Miller CH, Graham JB, Goldin LR, et al. Genetics of classic von Willebrand’s disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis. Blood. 1979;54(1):137-145.
13. Eikenboom JC, Castaman G, Kamphuisen PW, et al. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost. 2002;87(2):252-257.
14. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4(4):774-782.
15. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
16. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1): 112-121.
17. Tosetto A, Rodeghiero F, Castaman G, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost. 2007;5(4): 715-721.
18. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008; 111(7):3531-3539.
19. Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762-771.
20. Eikenboom J, Hilbert L, Ribba AS, et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009;7(8):1304-1312.
21. Hampshire DJ, Burghel GJ, Goudemand J, et al; EU-VWD and ZPMCB-VWD study groups. Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica. 2010; 95(12):2163-2165.
22. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev. 2006;20(2): 83-92.
23. Morelli VM, de Visser MC, van Tilburg NH, et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost. 2007;97(4):534-541.